Dr. JeanMarie Guenot Takes Fighting Cancer To A Whole New Level

Having attained her Ph.D. from the University of California in San Francisco and then later going further on to achieve her MBA from The Wharton School connected to The University of Pennsylvania, Guenot quickly took to the world of innovative medical intervention when she first started in on her chosen career through the Hoffman-La Roche company when she joined on in the year 1993 as their Team Leader and Principal Scientist in their Preclinical R&D.

Moving on and up quickly, Jeanmarie Guenot quickly shot to the forefront of her peers in her chosen industry to take up a position as an Associate for the Life Sciences arena at Atlas Venture where she stayed for three years before leaving in 2003 to take up the position as Vice President of the Corporate and Business Development sector at PDL BioPharma on guenotllc.com where she enjoyed furthering her education and practice through much extensive research in her five year stay at their company before moving on again to take part in Guenot, LLC where she stood as Managing Partner for one year from 2008 through to 2009.

Read more: Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies

After her one year stint at Guenot, LLC, JeanMarie Guenot took to the idea of creating her own company, so she founded and became the Partner and First Employee at her own company known as SKS Ocular, LLC, a ophthalmic startup company incubator that was designed to assist in the growth of progressive technologies for sustained release ocular drug delivery, AMD, and macular degeneration where she remained for three years before moving on again to engage in the cutting edge research going on at Amphivena Therapeutics Inc., where she stands as their Chief Executive Officer as well as their President.

Today, JeanMarie Guenot has her full attention placed on the development of bispecific antibodies that can redirect tetravalent T-cells in order to assist in finding the best possible sustainable treatments for hematologic malignancies such as certain cancers including Leukemia. Dr. JeanMarie Guenot has made herself into a vital part of the team at Amphivena Therapeutics Inc., and is taking huge, innovative steps into the future of sustainable medical intervention.

Learn more about Jeanmarie Guenot: http://www.businesswire.com/news/home/20170111005414/en/Maverick-Therapeutics-Takeda-Announce-Five-year-Collaboration-Advance